Skip to content

A randomised controlled trial of vitamin D supplementation vs placebo on cognitive and emotional outcomes

A randomised controlled trial of vitamin D supplementation vs placebo on cognitive and emotional outcomes in healthy volunteers

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12610000318088
Enrollment
210
Registered
2010-04-20
Start date
2010-04-26
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

There is a growing body of research indicating that vitamin D blood concentrations can impact on brain functioning. In particular, there is robust evidence in animal models showing that vitamin D deficiency during development impairs brain functioning in adulthood. However, no studies have examined whether enhancing vitamin D blood concentrations by vitamin D supplementation during adulthood can improve brain functioning. This study will assess whether increasing vitamin D blood concentrations via vitamin D supplementation in healthy adults improves various aspects of brain functioning such as attention, response inhibition, and general mood and emotions. We anticipate that this study will provide us with important information about the effects of enhancing vitamin D blood concentrations on brain function in healthy adults.

Interventions

Vitamin D (Cholecalciferol 5000 IU) capsules, 1 capsule daily for 6 weeks

Sponsors

The University of Queensland
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Primary purpose
Treatment

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

aged 18 years or over provision of consent to participate.

Exclusion criteria

1) current use of vitamin D or calcium supplements; 2) having past adverse reactions to vitamin supplements; 3) current or recent use of psychotropic medications or medications which may influence vitamin D absorption (e.g. cholestyramine, orlistat) 4) current or past diagnosis of psychotic disorders; 5) serious neurologic illnesses including stroke, brain tumours, head trauma, multiple sclerosis, epilepsy, movement disorders or migraine in treatment; 6) drug dependency on alcohol or illicit substances; 6) intellectual disability 7) pregnancy or current breast feeding, or potential to become pregnant during the trial; 8) history of severe renal impairment, 9) recent or current use of immunosuppressive therapy.

Outcome results

None listed

Source: ANZCTR · Data processed: Mar 27, 2026